Can ADIL's Q4 forecast break the EPS slump?

**Adial Pharmaceuticals Inc. (ADIL) is unlikely to break the EPS slump in Q4**, based on the available data and market analysis. Here's why:

1. **Current EPS Trend**: ADIL's EPS has been in a decline trend, with a recent quarter reporting an EPS of -$0.38 for the period ending September 30, 2024. This indicates a company is not profitable in the short term.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ADIL|ADIL.O|Adial|2024 Q1|20.363636363636363|-2.19|186|
|ADIL|ADIL.O|Adial|2024 Q2|-160.82474226804123|-0.59|186|
|ADIL|ADIL.O|Adial|2024 Q3|67.79661016949152|-0.38|186|

2. **Recent Performance**: The stock has experienced a significant decline, with a 46.7% loss so far this year. This suggests that the company is facing challenges that are reflected in its stock price and EPS.
3. **Analyst Expectations**: Analysts have lowered their earnings estimates, with the latest forecast anticipating an EPS of $-0.50 for Q3 2024. This indicates a continued expectation of losses in the near term.
4. **Institutional Activity**: Institutional investors have shown interest, with Virtu Financial LLC acquiring a new position in the company. However, this does not necessarily indicate an immediate turnaround in EPS.
5. **Market Capitalization and Valuation**: ADIL has a market capitalization of $13 million and a price-to-earnings ratio of -0.36, which may indicate that the company is not yet profitable and is not being valued based on traditional earnings metrics.

In conclusion, while ADIL has some institutional support and has made strides in regaining Nasdaq compliance and advancing its drug pipeline, the EPS slump is not expected to break in Q4 based on the current financial forecasts and market sentiment. The company's trajectory towards profitability will depend on the successful commercialization of its lead asset, AD04, and its ability to generate revenue from it.